KYOWA-KIRIN
7.8.2024 09:01:31 CEST | Business Wire | Press release
Kyowa Kirin International (KKI), a wholly owned subsidiary of Kyowa Kirin Co., Ltd. (TSE:4151, Kyowa Kirin) and a Japan-based global specialty pharmaceutical company, announced today the signing of a Promotion and Distribution Agreement with NewBridge Pharmaceuticals for the distribution of its existing rare disease portfolio across the Middle East and North Africa (MENA).
Under the terms of the agreement, NewBridge will commercialise CRYSVITA® (burosumab) for the treatment of X-Linked Hypophosphataemia (XLH) and Tumour-Induced Osteomalacia (TIO), as well as POTELIGEO® (mogamulizumab) for two subtypes of cutaneous T-cell lymphoma (CTCL), a rare non-Hodgkin’s lymphoma.
As part of the agreement, NewBridge will exclusively distribute the two products across MENA countries of Algeria, Iraq, Libya and Jordan. KKI and NewBridge also hope to collaboratively address a number of challenges facing the rare disease community in the region by supporting disease awareness, improving time to diagnosis, and improving access to innovative treatments indicated for rare and orphan diseases.
Jeremy Morgan, President of KKI, commented: “At Kyowa Kirin our purpose is to deliver life-changing medicines and make people smile. We are pleased to be entering into this agreement with NewBridge Pharmaceuticals who have a clear mission to transform the lives of MENA patients and their families. With a commitment to delivering life changing value for people impacted by under-diagnosed and under-served diseases, this agreement is key to ensuring patients living with XLH, TIO and CTCL are able to access the medicines they need, and is another positive step on our journey.”
"Given the high prevalence of rare diseases in the MENA region, I am personally inspired and proud that we at NewBridge are building on our existing partnership with Kyowa Kirin with the addition of their rare disease products to our region,” added Joe Henein, President & CEO of NewBridge Pharmaceuticals. “This collaboration totally aligns with our mission to provide access to new therapies for patients, aiming to alleviate their suffering and enhancing their quality of life."
About CRYSVITA (burosumab)
CRYSVITA (burosumab) is a recombinant human monoclonal antibody (mAb) that binds to the protein fibroblast growth factor 23 (FGF23). This has the impact of inhibiting the action of FGF23, allowing phosphate regulation in the body to be restored.1
About POTELIGEO (mogamulizumab)
Mogamulizumab is a first-in-class humanised mAb directed against CC chemokine receptor 4 (CCR4), a protein consistently expressed in both mycosis fungoides and Sézary syndrome2–4 once mogamulizumab binds to CCR4, it increases attraction of immune cells from the immune system to destroy the cancerous cells.5
About Kyowa Kirin
Kyowa Kirin aims to discover novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients affected by severe and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across our four regions—Japan, Asia Pacific, North America, and EMEA/International.
You can learn more about the business of Kyowa Kirin at: https://www.kyowakirin.com
About NewBridge Pharmaceuticals
NewBridge Pharmaceuticals is a regional specialty company with a comprehensive pharmaceutical platform of services and expertise, established to bridge the access gap and partner with global pharma and biotech companies to in-license and commercialise innovative therapeutics that address unmet medical needs into the Middle East and North Africa (MENA) regions.
For more information, please visit www.nbpharma.com
References
1Electronic Medicines Compendium. Crysvita 10 mg solution for injection. Available from: https://www.medicines.org.uk/emc/product/9779/smpc#gref. Last accessed: November 2023.
2Ferenczi K, et al. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol. 2002;119:1405–10.
3Yoshie O, et al. Frequent Expression of CCR4 in Adult T-Cell Leukemia and Human T-cell Leukemia Virus Type 1-transformed T cells. Blood. 2002;99(5):1505–11.
4Ishida T, et al. Clinical Significance of CCR4 Expression in Adult T-cell Leukemia/Lymphoma: Its Close Association With Skin Involvement and Unfavorable Outcome. Clin Cancer Res. 2003;9:3625–34.
5Duvic M, et al. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016;7(3):171–174.
KKI/INT/KKI/0959
Date of preparation: July 2024
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240807411936/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Named NVIDIA Partner Network ‘Rising Star Consulting Partner of the Year’ at NVIDIA GTC 202618.3.2026 03:30:00 CET | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has been recognized as the NVIDIA Partner Network (NPN) ‘Rising Star Consulting Partner of the Year’ at NVIDIA GTC 2026. The award recognizes LTM’s strong collaboration with NVIDIA and its growing impact in helping enterprises move from AI experimentation to scalable, enterprise-ready adoption. The NVIDIA Partner Network (NPN) brings together a global ecosystem of technology and consulting partners working closely with NVIDIA to deliver advanced AI solutions. Being an NPN partner is about collaborating deeply with NVIDIA to help clients transition from AI pilots to enterprise-scale deployments combining NVIDIA’s advanced AI technologies with LTM’s industry and domain expertise to drive real-world outcomes. The Rising Star Consulting Partner of the Year award highlights LTM’s momentum in delivering AI solutions that are production-grade, secure, and designed for enterprise scale. This NPN award is a significant rec
SES Successfully Prices €650 million of SPACE Hybrid Securities17.3.2026 23:00:00 CET | Press release
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN, OR AT ANY ADDRESS IN, THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE UNITED STATES) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE SECURITIES ACT)) OR IN OR INTO ANY JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT (SEE “OFFER AND DISTRIBUTION RESTRICTIONS” BELOW). SES Financing S.à r.l., a wholly owned subsidiary of SES, announced the successful launch and pricing of the PNC5.25 Subordinated Perpetual with Automatic Conversion Events (“SPACE”) hybrid transaction, guaranteed on a subordinated basis by SES and SES Americom. SES Financing S.à r.l. is rated Ba1 (stable) and BBB- (stable) by
Rimini Street Announces Participation in the ROTH Capital Partners 38th Annual Investor Conference17.3.2026 22:37:00 CET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced the following upcoming ROTH Capital Partners Investor Conference, March 23 and 24, 2026, in Laguna Niguel, California: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317799301/en/ Rimini Street Announces Participation in the ROTH Capital Partners 38th Annual Investor ConferenceSeth Ravin, CEO, and Dean Pohl, vice president, treasurer and investor relations, will participate in one-on-one and small group meetings (Seth Ravin, March 23 only) Seth Ravin will participate in a panel discussion led by ROTH Capital Partners Managing Director, Senior Research Analyst Rich Baldry, titled “Software: Risks, Opportunities & Realities of the AI Emergence” on March 23, 2:00 p.m. – 2:55 p
The World Goes Green for St Patrick’s Day 202617.3.2026 17:50:00 CET | Press release
Ireland Leads a Global Celebration of Culture and Community This March, St Patrick’s Day invites people all over the world to become Irish for a day, as cities and communities across the globe unite in a shared celebration of heritage, culture and connection. From parades and parties to the famous global greenings, the festival’s spirit reaches far beyond Ireland’s shores. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260306890851/en/ St Patrick's Festival Kilkenny City 2022 The World Goes Green Ireland’s national holiday, St Patrick’s Day unites a global community in a vivid moment of celebration. Each year, hundreds of iconic landmarks are illuminated in green, from the Empire State Building in New York and the Leaning Tower of Pisa in Italy to Niagara Falls in Canada and the Wallace Monument in Scotland. These striking displays reflect the far-reaching connections of Irish communities overseas and the worldwide affection
USD 1.63 Billion In 72 Hours: Manchester City Yas Residences by Ohana Development Sets New Sales Record In Abu Dhabi17.3.2026 16:44:00 CET | Press release
• 35% of investors are Emiratis, while 65% are expatriates and international investors • Milestone reflects strong demand for the project and continued confidence in the UAE’s real estate sector Ohana Development, a leading UAE real estate developer renowned for its luxury projects, has recorded USD 1.63 billion in sales within 72 hours for Manchester City Yas Residences by Ohana, a gated waterfront community located along Yas Canal in Abu Dhabi, setting a new sales record in the emirate’s real estate market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260317595867/en/ Manchester City Yas Residences by Ohana (Photo: AETOSWire) Investors queued at the sales launch, reflecting the strong demand for the project. Of the investors, 35% are Emiratis, while 65% are expatriates and international buyers. In response to this significant interest, Ohana Development is expected to release additional inventory from the project soon. I
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom